Dr David Thomson is a Consultant Clinical Oncologist, appointed as Clinical Director of the Greater Manchester Head and Neck Cancer Pathway Board, prioritising the improvement of survival outcomes and long-term quality of life for patients treated for head and neck cancer.

Dr Thomson qualified from Oxford University Medical School in 2004 with a First-Class honours intercalated degree in Physiological Sciences. He later undertook a research Fellowship at the University of Manchester with an attachment to the University of Pennsylvania in the United States and was awarded a Doctor of Medicine (MD) research degree in 2015. His interest in medical education led him to complete a Postgraduate Certificate in Medical Education with Distinction in 2014. The following year, he was appointed Consultant Clinical Oncologist at The Christie and Honorary Senior Lecturer at The University of Manchester, specialising in the treatment of head and neck cancer.

Dr Thomson is a member of the National Cancer Research Institute (NCRI) group for head and neck cancer. He serves as the research lead for the head and neck team at The Christie and is the Deputy Chief Investigator for the UK phase 3 NIMRAD trial, which assesses the benefit of hypoxia modification using nimorazole with radiotherapy in patients unsuitable for concurrent chemotherapy. Additionally, he is the Principal Investigator for several portfolio studies, a Proton Beam Therapy national panel member, and the policy lead for head and neck cancer. Dr Thomson is also a member of the Clinical Innovation Board and the clinical lead for electronic patient-reported outcomes in head and neck cancer at The Christie.

Dr Thomson's areas of expertise include radiotherapy, chemotherapy, clinical oncology, cancer care, and head and neck cancers. He has been dedicated to advancing the field of oncology since his appointment in 2015, continually striving to enhance patient care and treatment outcomes.